Sujatha Baddam1, Inmaculada Aban2, Lee Hilliard1, Thomas Howard1, David Askenazi3, Jeffrey D Lebensburger4. 1. Pediatric Hematology and Oncology, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 512, Birmingham, AL, 35233, USA. 2. Department of Biostatistics, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 512, Birmingham, AL, 35233, USA. 3. Pediatric Nephrology, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 512, Birmingham, AL, 35233, USA. 4. Pediatric Hematology and Oncology, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 512, Birmingham, AL, 35233, USA. jlebensburger@peds.uab.edu.
Abstract
BACKGROUND: Patients who develop sickle cell disease (SCD) nephropathy are at a high risk for mortality. The pathophysiology of vaso-occlusive pain crisis may contribute to acute kidney injury (AKI). Non-steroidal anti-inflammatory drugs, known inducers of AKI, are used to treat pain crises. Multiple gaps exist in the knowledge about the impact of AKI in SCD. METHODS: We conducted a 2-year retrospective review of AKI events in patients admitted for vaso-occlusive crisis. AKI was defined by an increase of ≥0.3 mg/dL or 50% in serum creatinine from baseline. Laboratory values and ketorolac administration by days and dose (mg/kg) were identified from hospital records. A generalized mixed effects model for binary outcomes evaluated AKI based on laboratory variables and ketorolac administration. A generalized mixed Poisson effects model analyzed the association of AKI with hospital length of stay. RESULTS: Thirty-three out of 197 admissions for vaso-occlusive pain crisis (17%) were associated with AKI. Fifty-two percent of the cases presented to the Emergency Room (ER) with AKI. Every one unit decrease in hemoglobin from baseline to admission increased the risk of AKI by 49%. Among patients who received ketorolac for pain, both total days and doses of ketorolac were associated with AKI. Finally, patients with pain and AKI required longer periods of hospitalization than patients without AKI. CONCLUSION: Acute kidney injury during sickle cell pain crisis is common and may be an important modifiable risk factor for developing chronic kidney disease (CKD). Further studies are needed to determine the impact of nephrotoxic medications on progressive SCD nephropathy.
BACKGROUND:Patients who develop sickle cell disease (SCD) nephropathy are at a high risk for mortality. The pathophysiology of vaso-occlusive pain crisis may contribute to acute kidney injury (AKI). Non-steroidal anti-inflammatory drugs, known inducers of AKI, are used to treat pain crises. Multiple gaps exist in the knowledge about the impact of AKI in SCD. METHODS: We conducted a 2-year retrospective review of AKI events in patients admitted for vaso-occlusive crisis. AKI was defined by an increase of ≥0.3 mg/dL or 50% in serum creatinine from baseline. Laboratory values and ketorolac administration by days and dose (mg/kg) were identified from hospital records. A generalized mixed effects model for binary outcomes evaluated AKI based on laboratory variables and ketorolac administration. A generalized mixed Poisson effects model analyzed the association of AKI with hospital length of stay. RESULTS: Thirty-three out of 197 admissions for vaso-occlusive pain crisis (17%) were associated with AKI. Fifty-two percent of the cases presented to the Emergency Room (ER) with AKI. Every one unit decrease in hemoglobin from baseline to admission increased the risk of AKI by 49%. Among patients who received ketorolac for pain, both total days and doses of ketorolac were associated with AKI. Finally, patients with pain and AKI required longer periods of hospitalization than patients without AKI. CONCLUSION:Acute kidney injury during sickle cell pain crisis is common and may be an important modifiable risk factor for developing chronic kidney disease (CKD). Further studies are needed to determine the impact of nephrotoxic medications on progressive SCD nephropathy.
Authors: Karl A Nath; Joseph P Grande; Anthony J Croatt; Elena Frank; Noel M Caplice; Robert P Hebbel; Zvonimir S Katusic Journal: Am J Pathol Date: 2005-04 Impact factor: 4.307
Authors: Jeffrey D Lebensburger; Tamara I Pestina; Russell E Ware; Kelli L Boyd; Derek A Persons Journal: Haematologica Date: 2010-04-07 Impact factor: 9.941
Authors: Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang Journal: Blood Adv Date: 2020-06-23
Authors: Santosh L Saraf; Maya Viner; Ariel Rischall; Rasha Raslan; Binal N Shah; Xu Zhang; Jin Han; Michel Gowhari; Shivi Jain; Robert E Molokie; Roberto F Machado; James P Lash; Victor R Gordeuk Journal: Blood Date: 2018-08-23 Impact factor: 22.113
Authors: Rima S Zahr; Marianne E Yee; Jack Weaver; Katherine Twombley; Raed Bou Matar; Diego Aviles; Rajasree Sreedharan; Michelle N Rheault; Rossana Malatesta-Muncher; Hillarey Stone; Tarak Srivastava; Gaurav Kapur; Poornima Baddi; Oded Volovelsky; Jonathan Pelletier; Rasheed Gbadegesin; Wacharee Seeherunvong; Hiren P Patel; Larry A Greenbaum Journal: Pediatr Nephrol Date: 2019-04-03 Impact factor: 3.714
Authors: Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy Journal: Blood Adv Date: 2019-12-10
Authors: Jamie Oakley; Rima Zahr; Inmaculada Aban; Varsha Kulkarni; Rakesh P Patel; Julia Hurwitz; David Askenazi; Jane Hankins; Jeffrey Lebensburger Journal: Am J Hematol Date: 2018-05-14 Impact factor: 10.047
Authors: Essa Hariri; Anthony Mansour; Andrew El Alam; Yazan Daaboul; Serge Korjian; Sola Aoun Bahous Journal: Int Urol Nephrol Date: 2018-01-30 Impact factor: 2.370